131 related articles for article (PubMed ID: 32006673)
1. Preclinical pharmacokinetic, biodistribution, radiation dosimetry, and toxicity studies of
Biabani Ardakani J; Talebpour Amiri F; Khorramimoghaddam A; Abbasi A; Molavipordanjani S; Hosseinimehr SJ
Regul Toxicol Pharmacol; 2020 Apr; 112():104591. PubMed ID: 32006673
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of
Shahsavari S; Shaghaghi Z; Abedi SM; Hosseinimehr SJ
Int J Radiat Biol; 2020 Apr; 96(4):502-509. PubMed ID: 31829777
[No Abstract] [Full Text] [Related]
3. Molecular Imaging of HER2 Expression in Breast Cancer patients Using the [
Biabani Ardakani J; Abedi SM; Mardanshahi A; Shojaee L; Zaboli E; Khorramimoghaddam A; Nosrati A; Sabahno H; Banimostafavi ES; Hosseinimehr SJ
Clin Breast Cancer; 2023 Feb; 23(2):219-230. PubMed ID: 36581518
[TBL] [Abstract][Full Text] [Related]
4. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
5. SPECT/CT Imaging of the Novel HER2-Targeted Peptide Probe
Li L; Wu Y; Wang Z; Jia B; Hu Z; Dong C; Wang F
J Nucl Med; 2017 May; 58(5):821-826. PubMed ID: 28104744
[TBL] [Abstract][Full Text] [Related]
6. An improved
Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
[TBL] [Abstract][Full Text] [Related]
7. The Potential Usefulness of
Avan Z; Biabani Ardakani J; Talebpour Amiri F; Abedi SM; Hosseinimehr SJ
Cancer Biother Radiopharm; 2022 Nov; 37(9):862-869. PubMed ID: 32898439
[No Abstract] [Full Text] [Related]
8. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99m HYNIC-annexin V: a potential radiopharmaceutical for the in-vivo detection of apoptosis.
Ohtsuki K; Akashi K; Aoka Y; Blankenberg FG; Kopiwoda S; Tait JF; Strauss HW
Eur J Nucl Med; 1999 Oct; 26(10):1251-8. PubMed ID: 10541822
[TBL] [Abstract][Full Text] [Related]
10. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
11. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates.
Jia B; Liu Z; Zhu Z; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Mol Imaging Biol; 2011 Aug; 13(4):730-6. PubMed ID: 20694579
[TBL] [Abstract][Full Text] [Related]
12. Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with (99m)Tc-peptide-Z(HER2:342).
Zhang J; Zhao X; Wang S; Wang N; Han J; Jia L; Ren X
Nucl Med Biol; 2015 Jun; 42(6):541-6. PubMed ID: 25735223
[TBL] [Abstract][Full Text] [Related]
13. Plasma protein binding of (99m)Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides.
Ono M; Arano Y; Mukai T; Uehara T; Fujioka Y; Ogawa K; Namba S; Nakayama M; Saga T; Konishi J; Horiuchi K; Yokoyama A; Saji H
Nucl Med Biol; 2001 Feb; 28(2):155-64. PubMed ID: 11295426
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab.
Lam K; Chan C; Done SJ; Levine MN; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):78-84. PubMed ID: 25459109
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.
Van de Wiele C; Dumont F; Dierckx RA; Peers SH; Thornback JR; Slegers G; Thierens H
J Nucl Med; 2001 Nov; 42(11):1722-7. PubMed ID: 11696645
[TBL] [Abstract][Full Text] [Related]
16. A Pretargeted Imaging Strategy for EGFR-Positive Colorectal Carcinoma via Modulation of Tz-Radioligand Pharmacokinetics.
Qiu L; Lin Q; Si Z; Tan H; Liu G; Zhou J; Wang T; Chen Y; Huang Y; Yu T; Jin M; Cheng D; Shi H
Mol Imaging Biol; 2021 Feb; 23(1):38-51. PubMed ID: 32914391
[TBL] [Abstract][Full Text] [Related]
17. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
18. Development of a
Zhao L; Liu C; Xing Y; He J; O'Doherty J; Huang W; Zhao J
Mol Pharm; 2021 Sep; 18(9):3616-3622. PubMed ID: 34328338
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of
Maleki F; Masteri Farahani A; Sadeghzadeh N; Mardanshahi A; Abediankenari S
Chem Biol Drug Des; 2020 Nov; 96(5):1223-1231. PubMed ID: 32426902
[TBL] [Abstract][Full Text] [Related]
20. Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conjugated to the antimicrobial peptide UBI 29-41.
Welling MM; Visentin R; Feitsma HI; Lupetti A; Pauwels EK; Nibbering PH
Nucl Med Biol; 2004 May; 31(4):503-9. PubMed ID: 15093821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
